Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study

OBJECTIVE: To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in patients with ankylosing spondylitis. METHODS: Patients opting to enrol had completed 2 years’ treatment in the MEASURE 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Jürgen, Baraliakos, Xenofon, Deodhar, Atul, Poddubnyy, Denis, Emery, Paul, Delicha, Eumorphia M, Talloczy, Zsolt, Porter, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477523/
https://www.ncbi.nlm.nih.gov/pubmed/30590813
http://dx.doi.org/10.1093/rheumatology/key375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477523/
https://www.ncbi.nlm.nih.gov/pubmed/30590813
http://dx.doi.org/10.1093/rheumatology/key375

Ejemplares similares